New Chief Medical Officer joins Khondrion

pharmafile | February 7, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Khondrion has revealed that Dr Rob van Maanen has joined the company as its new Chief Medical Officer (CMO).

Dr van Maanen’s career has spanned more than 20 years and seen him take on roles at major industry names such as Roche, Astellas and Eisai. In the role, he will manage the company’s medical operations and clinical strategy.

As part of his remit, Dr van Maanen will also supervise the development of the oral small-molecule drug candidate Sonlicromanol for the treatment of mitochondrial diseases, a key asset for the firm for Khondrion which entered Phase 2b trials in January.

“We are delighted to welcome Rob to the Khondrion team. With this appointment we are preparing the company for late stage development of the pipeline and the expansion of our clinical capabilities, which are important in helping us to accomplish our mission of bringing clinically meaningful medicines to patients living with devastating mitochondrial diseases,” Professor Dr Jan Smeitink, Chief Executive Officer at Khondrion. “I would like to thank Edwin Spaans, who served as our CMO until recently, for all his work assisting us in bringing our lead asset towards its Phase 2b development.”

Dr van Maanen said of his appointment: “This is an exciting time to join Khondrion as it progresses its pipeline in mitochondrial disease. The company’s journey so far, bringing lead asset, Sonlicromanol, all the way through discovery to Phase 2b development within just seven years, is truly remarkable. Khondrion’s pipeline also offers possibilities in the treatment of other serious diseases with high unmet need and I look forward to being part of a team whose research offers such potential to improve outcomes for patients.”

Related Content

No items found

Latest content